Common Drug Increases Deaths in Atrial Fibrillation Patients
http://www.sciencedaily.com/releases/2012/11/...154220.htm
ScienceDaily (Nov. 27, 2012) — Digoxin, a drug widely used to treat heart disease, increases the possibility of death when used by patients with a common heart rhythm problem ? atrial fibrillation (AF), according to new study findings by University of Kentucky researchers. The results have been published in the European Heart Journal, and raises serious concerns about the expansive use of this long-standing heart medication in patients with AF.
UK researchers led by Dr. Samy Claude Elayi, associate professor of medicine at UK HealthCare's Gill Heart Institute, analyzed data from 4,060 AF patients enrolled in the landmark Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial. This analysis was intended to determine the relationship between digoxin and deaths in this group of patients with atrial fibrillation, and whether digoxin was directly responsible for some deaths.
"These findings raise important concerns about the safety of digoxin, one of the oldest and most controversial heart drugs," said Dr. Steven E. Nissen, chair of cardiovascular medicine at the Cleveland Clinic. "Although considered obsolete by some authorities, digoxin is still widely used. A thorough review by the FDA is warranted to determine whether regulatory action is needed, including stronger warnings about the use of digoxin in patients with atrial fibrillation. "
Digoxin is extracted from the foxglove plant and it helps the heart beat more strongly, and at a slower heart rate. It is commonly used in AF patients and in patients with heart failure. However, it can be problematic to use successfully as there is a narrow dose range at which it is effective, and beyond which it can be dangerous.
Though digoxin has been used by physicians treating AF for decades, until now, there has been limited evidence demonstrating the effect of digoxin in patients with this condition. "Digoxin in AF patients has hardly been studied," said Elayi. "The main prospective randomised controlled trials available with digoxin were performed in patients with heart failure and sinus rhythm, and routinely excluded AF patients."
The results of the analysis found that digoxin was associated with a 41 percent increase in deaths from any cause after controlling for other medications and risk factors. An increase in deaths occurred regardless of gender or the presence or absence of underlying heart failure. Digoxin was also associated with a 35 percent increase in deaths from cardiovascular causes, and a 61 percent increase in deaths from arrhythmias or problems with the rate or rhythm of the heartbeat.
"Within five years of use, one additional AF patient out of six taking digoxin ? compared to those not on digoxin in the AFFIRM trial? will die from any cause," Elayi said. "One additional patient out of eight will die from cardiovascular causes, and one additional patient out of 16 will die from arrhythmias.
"This study calls into question the widespread use of digoxin in patients with AF, particularly when used for controlling AF rate in a similar way as in the AFFIRM trial," Elayi said. "These findings suggest that physicians should try to control a patient's heart rate by using alternatives such as beta-blockers or calcium blockers ,as a first line treatment.
"If digoxin is used, prescribers should use a low dose with careful clinical follow up, evaluate potential drug interactions when starting new medications, and monitor digoxin levels."
In addition, patients should also be aware of potential toxicity and see their physicians immediately in specific clinical situations, he said. For instance, if they experience increasing nausea, vomiting, palpitations or syncope, as those may precede arrhythmic death, Elayi added.
The researchers say that the mechanism by which digoxin increases deaths among patients is unclear. Deaths from classic cardiovascular causes -- whether or not they are due to arrhythmia -- can partly but not entirely explain it. This suggests there must be some additional mechanism that remains to be identified, said Elayi.
"Our study underscores the importance of reassessing the role of digoxin in the contemporary management of AF in patients with or without HF," concluded the authors in their paper. "There is a need for further studies of the drug's use, particularly in systolic heart failure patients and AF -- patients that would, in theory, benefit the most from digoxin."
Common Drug Increases Deaths in Atrial Fibrillation
Top 10 Most Recent News Articles
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move
Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...
Continue Reading
RBI Prices $1 Billion of Secured Notes Due 2031, 2036
A billion dollars of fresh paper just landed on Restaurant Brands International’s balance-sheet doorstep, and this one deserves more than the usual sleepy glance at a financing release. RBI has priced $500 million of 6.00% senior secured notes due 2031 and another $500 million of 6.40% senior secured notes due 2036. The expected closing date is November 24, 2026,...
Continue Reading
Midea's Cooling Systems Take Center Stage at DCW ME
AI Surge Demands Cooler Solutions Alright, who'd guess that data centers would feel the heat—literally—like a welder's furnace in Abu Dhabi? As AI demand burns hotter across the Middle East, data centers are sweating it out against 50°C-plus temperatures. We're talking about some serious pressure on traditional cooling methods that just can’t cut it anymore....
Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win
Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...
Continue Reading
Floating Solar Gets a Serious Test in Central New York
A flooded quarry pit outside Cortlandville is getting a second career, and that is more interesting than another solar announcement draped across empty acreage. Third Pillar Power has started construction on Crown City Solar at Suit-Kote Corporation's active Polkville Crushed Stone Facility, pairing a working mine, asphalt plant, and storage terminal with what the...
Continue Reading
Visa Direct Tests Stablecoin Prefunding in Asia-Pacific
Cross-border payouts have always had an ugly little problem: money can move digitally in theory, then sit around waiting for banks to wake up in practice. Triple-A’s new collaboration with Visa Direct aims straight at that nuisance in Asia-Pacific, allowing eligible clients to use stablecoins to prefund cross-border payouts while the recipient still gets local currency....
Continue Reading
My Home Delivery's Bold Move in Big & Bulky Sector
Redefining Big & Bulky Deliveries with AI Let me tell you, the logistics world isn't for the timid, and My Home Delivery (MHD) is swinging for the fences with their latest tech platform. These folks are rolling out an AI-driven system that promises to turn the bulky goods market on its head. Imagine moving your brand new fridge or that king-size bed across town without...
Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious
Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...
Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend
A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...
Continue Reading
Labcorp's Brazil Trial Push Has Promise and Plenty to Prove
Brazilian clinical-trial kit deliveries may soon spend less time tangled in international shipping. That is the practical heart of Labcorp's newly announced collaboration with Grupo Fleury, and frankly, practical is plenty good in this business. Labcorp plans to begin assembling clinical-trial kits locally in Brazil in early 2027, then add laboratory operations by the end...
Continue ReadingTop 5 Most Recently Viewed Articles
Hormel Foods Welcomes Debbra Schoneman to Board of Directors
Debbra Schoneman Joins Hormel Foods Board of Directors Hormel Foods Corporation (NYSE: HRL), a leader in the global branded food sector, is excited to announce the election of Debbra Schoneman to its Board of Directors. This pivotal decision aligns with the company's ongoing dedication to excellence and innovative leadership. Debbra Schoneman's Background Jim Snee, the...
Continue Reading
Superorganism Secures $25.9M for Biodiversity Ventures
Superorganism Secures $25.9M for Biodiversity Ventures Nature and technology fund backed by leading investors aims to redefine how capital advances biodiversity Superorganism, a pioneering venture capital firm focusing on technology solutions for biodiversity, recently announced the successful closure of its debut fund, garnering commitments amounting to $25.9 million....
Continue Reading
Teamsters Local 838 Welcomes First Student Workers in Missouri
Teamsters Local 838 Welcomes First Student Workers In a significant development for school transportation workers, more than 100 bus drivers and monitors at First Student in Missouri have united under Teamsters Local 838. This successful vote marks a substantial step in expanding Teamster representation within the school transportation sector, ensuring these workers have...
Continue Reading
Exploring Promising Tech Innovators: Beyond the Giants
Understanding the Tech Landscape The technology sector has captured the spotlight as one of the leading areas of growth in recent times. Yet, within this vast landscape, not all players enjoy the same level of success. Many people automatically think of established giants when they hear "tech"—companies often dubbed as the Magnificent Seven, including major players such...
Continue Reading
Highland Copper Innovates with New Drilling and Flotation Tech
Highland Copper's New Drilling Program for Metallurgy Highland Copper Company Inc. is taking an exciting step forward with a new drilling program aimed at exploring and optimizing its mining operations. This initiative demonstrates Highland Copper's dedication to utilizing innovative and sustainable mining methods, significantly enhancing its project economics. Focusing...
Continue Reading